Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Theranos CEO: Company Gained More Patients after WSJ Investigation

By Drug Discovery Trends Editor | December 11, 2015

CHIANGMAI, THAILAND - April 30, 2015: Photo of Forbes article page about Elizabeth Holmes on a ipad monitor screen through a magnifying glass. Credit: GongTo/Shutterstock​Theranos, the medical-testing company valued at $9 billion, is doing just fine despite a Wall Street Journal (WSJ) investigation questioning the effectiveness of the firm’s technology, according to a new interview conducted at the Forbes Healthcare Summit.

Elizabeth Holmes, the CEO of Theranos, told moderator Matthew Herper her enterprise experienced its highest volume of patients taking its blood tests after the WSJ story came out.

Theranos specializes is in a slew of blood tests said to offer a cheaper, accurate alternative to standard clinical lab diagnostics. The company claimed its products could identify traces of herpes simplex 1 from a single drop of blood.

The WSJ report, though, explained Theranos was using its proprietary technology named Edison to analyze a fraction of submitted tests while relying on traditional lab tools from other companies to analyze the remainder.

Holmes’s company has denied these allegations, but she told Herper she saw an opportunity to help a national audience better understand how Theranos’s tests work, according to Business Insider.

Holmes, however, told Herper she felt confident her company can handle more controversy if it arises as it tries to get regulatory approval from the Food and Drug Administration (FDA) for its finger-stick tests.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE